You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 278 Real-life data on gynecological sarcoma – therapeutic strategies for primary treatment – results of the german sarcoma registry REGSA (NOGGO RU1)

Article Text

Article menu

Download PDFPDF

Miscellaneous
278 Real-life data on gynecological sarcoma – therapeutic strategies for primary treatment – results of the german sarcoma registry REGSA (NOGGO RU1)
Free
  1. E Roser1,
  2. F Schmidt1,
  3. D Zocholl2,
  4. L Hanker3,
  5. ML Poelcher4,
  6. M Frank5,
  7. D Hornung6,
  8. T Fehm7,
  9. C Traut8,
  10. D Denschlag9,
  11. B Schmalfeldt10,
  12. J Terpe11,
  13. F Marmé12,
  14. G Bauerschmitz13,
  15. M Keller14,
  16. K Pietzner1 and
  17. J Sehouli1
  1. 1Charité – Universitätsmedizin Berlin, Charité Campus Virchow Clinic, Department of Gynecology with Center for Oncological Surgery, Berlin, Germany
  2. 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany
  3. 3University Clinic of Schleswig-Holstein, Campus Lübeck, Department of Gynecology and Obstetrics, Lübeck, Germany
  4. 4Rotkreuzklinikum Munich, Department of Gynecology, Munich, Germany
  5. 5Ortenau Klinikum Offenburg-Kehl, Department of Gynecology and Obstetrics, Offenburg, Germany
  6. 6Diakonissenkrankenhaus Karlsruhe, Vidiakliniken, Department of Obstetrics and Gynecology, Karlsruhe, Germany
  7. 7University Clinic of Duesseldorf , Department of Gynecology, Duesseldorf, Germany
  8. 8St. Elisabeth Hospital Köln-Hohelind, Department of Gynecology and Obstetrics, Köln, Germany
  9. 9Hochtaunus-Kliniken , Department of Gynecology, Bad Homburg, Germany
  10. 10University Medical Center Hamburg Eppendorf, Department of Gynecology, Hamburg, Germany
  11. 11Klinikum Südstadt Rostock , Department of Gynecology, Rostock, Germany
  12. 12Medical Faculty Mannheim – University Hospital Mannheim – Heidelberg University, Department of Gynecology, Mannheim, Germany
  13. 13University Medical Center Göttingen, Department of Gynecology , Göttingen, Germany
  14. 14North-Eastern German Society of Gynaecological Oncology, NOGGO e. V., Berlin, Germany

Abstract

Introduction/Background Gynecological Sarcomas (GS) account for only about 3% of all gynecological malignancies. They are known for their poor prognosis and lack of promising treatment options. Due to the rarity and heterogeneity of GS there is only little consensus regarding the optimal therapeutic strategies throughout all possible situations of the disease. REGSA is by date the largest gynecological registry for sarcoma in Germany.

Methodology Primary inclusion criteria was histologically confirmed diagnosis of sarcoma or STUMP of the female genital tract or sarcoma of the breast. Participating centers were authorized to enter data of sarcoma patients into electronic Case Report Forms. For the work presented here data on therapeutic strategies for primary treatment were analyzed descriptively.

Results From August 2015 till February 2021, 723 sarcoma patients were included by a total of 120 centers. Real-life data on therapeutic strategies for primary treatment was available in 600 cases. 571 patients underwent surgical treatment. In 465 patients a hysterectomy was performed, 200 had no further surgical interventions. An additional salpingoophorectomy was performed in 251 cases. Lymphonodectomy, omentectomy or intestinal resection was performed in less than 15% each. 21.4% of patients received chemo- or targeted therapies. Mono chemotherapy was administered more often than a combination chemotherapy. Anthracyclines were the most commonly used substances. 42 patients, mainly patients with Low-grade Endometrial Stromal Sarcoma received an anti-hormonal treatment and 31 patients underwent radiotherapy.

Conclusion Despite the limitations which arise from the structure of a clinical registry, the presented real life data of 600 patients are by date one of the largest analyses of the therapeutic strategies used for GS. Further trials are urgently needed to gain more information about treatment modalities, therapy response and patient-reported outcomes in order to implement new treatment strategies.

https://doi.org/10.1136/ijgc-2021-ESGO.258

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.